ClinicalTrials.gg
Active, not recruitingNCT06606106Updated Sep 30, 2026

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

A Phase 1 interventional study of LY3537031 and Placebo in Overweight and Obesity, sponsored by Eli Lilly and Company. Active, not recruiting at 5 sites in United States. Open to participants aged 22 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Updated Sep 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
22 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 118 studies in Obesity by Eli Lilly and Company — 30 open to participants now, 54 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Planned enrollment
52nd of 117
302 · median 267
Started
2024
with 19 others
Phase 1
40 of 118
8 open now
Primary completion
2026-11
later than 3 of 53 live
Registered
54th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 52nd largest by planned enrollment of the 117 interventional ones that give a count, is one of 20 that started in 2024, is one of 40 in phase 1, reaches primary completion later than 3 of the 53 other live ones, and was the 54th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

30 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 22 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants.

Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 49 weeks excluding a screening period.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

This study's planned enrollment of 302 is above the median of 67 across 9,027 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a within the range of:

    • Parts A and D: 27.0 to 45.0 kilogram per square meter (kg/m²)
    • Parts B and C: 22.0 to 26.9 kg/m²
  • Parts B and C: Weigh 60 kg (80 pounds (lbs)) or more at screening
  • Have no significant (not more than 5%) self-reported weight gain or loss in the past 3 months prior to screening
  • Have a thyroid stimulating hormone (TSH) value within normal local laboratory ranges.

Exclusion criteria

Exclusion Criteria:

  • Have undergone any form of bariatric surgery
  • Participants who are lactating
  • Have taken medications that promote weight loss within 90 days before screening
  • Have a serum calcitonin level (at screening) of greater than or equal to 35 nanograms per liter (ng/L) (35 picograms per milliliter (pg/mL), 10.2 picomoles per liter (pmol/L))
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
302 participants (estimated)

Study arms

  • Experimental
    LY3537031 Part A (Cohorts 1-7)

    Multiple-ascending doses of LY3537031 administered subcutaneously (SC)

    Drug: LY3537031

  • Placebo comparator
    Placebo Part A

    Placebo administered SC

    Drug: Placebo

  • Experimental
    LY3537031 Part B (Cohorts 8-11)

    Multiple-ascending doses of LY3537031 administered SC

    Drug: LY3537031

  • Placebo comparator
    Placebo Part B

    Placebo administered SC

    Drug: Placebo

  • Experimental
    LY3537031 Part C (Cohorts 12-15)

    Multiple-ascending doses of LY3537031 administered SC

    Drug: LY3537031

  • Placebo comparator
    Placebo Part C

    Placebo administered SC

    Drug: Placebo

  • Experimental
    LY3537031 Part D (Cohorts 16-19)

    Multiple-ascending doses of LY3537031 administered SC

    Drug: LY3537031

  • Placebo comparator
    Placebo Part D

    Placebo administered SC

    Drug: Placebo

Interventions

  • Administered SC

  • DrugPlacebo

    Administered SC

07

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline to Study Completion (Up to 56 Weeks)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3537031

    Time frame: Predose on Day 1 through Week 56

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of LY3537031

    Time frame: Predose on Day 1 through Week 56

  3. Pharmacodynamic (PD): Change from Baseline in Body Weight

    Time frame: Baseline up to Week 56

  4. PD: Change from Baseline in Fasting Glucose

    Time frame: Baseline up to Week 56

  5. PD: Change from Baseline in Oral Glucose Tolerance Test (OGTT) Results

    Time frame: Baseline up to Week 56

  6. PD: Change from Baseline in AUC of Glucose

    Time frame: Baseline Up to Week 56

  7. PD: Change from Baseline in Insulin Levels

    Time frame: Baseline Up to Week 56

  8. PD: Change from Baseline in Connecting Peptide (C-peptide) Levels

    Time frame: Baseline Up to Week 56

  9. PD: Change from Baseline in Cmax of Acetaminophen to Assess the Delay in Gastric Emptying

    Time frame: Baseline up to Week 56

  10. PD: Change from Baseline in AUC of Acetaminophen to Assess the Delay in Gastric Emptying

    Time frame: Baseline Up to Week 56

  11. PD: Change from Baseline in Time to Peak Drug Concentration (Tmax) of Acetaminophen to Assess the Delay in Gastric Emptying

    Time frame: Baseline Up to Week 56

08

Study locations

5 sites
09

References and documents

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Nov 2026, 26 months after the start.

Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 26 months is above that.

Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jul 2026 → Nov 2026 and completion Jul 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Sep 20, 2024
StartActual
Sep 5, 2024
Primary completionEst.
Nov 2026was Jul 2026
CompletionEst.
Nov 2026was Jul 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Nov 2026
Sep 30, 2026
Study completion
Jul 2026→Nov 2026
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Jul 2026→Nov 2026
    Study completion Jul 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06606106
Responsible party
Sponsor
First posted
Sep 20, 2024
Start date
Sep 5, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brenipatide

Start the discussion